While considered highly necessary from a health economic standpoint as well as from a clinical point of view, currently clinical response to anti-TNFα treatment cannot be predicted in IBD patients (van der Valk et al., 2014; Van der Valk et al., 2016), (Lopetuso et al., 2017), (D’Haens and Deventer, 2021), (Targownik et al., 2019). This evidence concerns the gene TNF and inflammatory bowel disease.